Vericel Corporation
Vericel Corporation is a biopharmaceutical company developing cellular therapies for sports medicine and severe burn care markets in North America. Products include MACI for knee cartilage repair, Epicel for skin replacement, and NexoBrid for eschar removal in thermal burns.
Overview
Strengths
- High-quality earnings: over the last 6 years, free cash flow added up to 3,060% of reported net income.
- Consistent growth: revenue has compounded at 17.3% a year over 5 years, rising every year.
Weaknesses
- Our discounted cash flow target price (5.20 USD) is 90% below the current price.
- Unstable profitability: operating margin ranged from -10% to 4% over the last 6 years, with operating losses in 3 of them.
- Valued at a premium to its Biotechnology peers: EV/EBITDA 88.6x vs. a median of 15.0x.
- Earnings are projected to decline (-10.0% per year).
Key Financial Data